Monday, November 4, 2024
HomeTagsDdBCMA

ddBCMA

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced that...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics